Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-12

AUTHORS

Antoine Adenis, Christelle de la Fouchardiere, Bernard Paule, Pascal Burtin, David Tougeron, Jennifer Wallet, Louis-Marie Dourthe, Pierre-Luc Etienne, Laurent Mineur, Stéphanie Clisant, Jean-Marc Phelip, Andrew Kramar, Thierry Andre

ABSTRACT

BACKGROUND: Randomized trials have shown a survival benefit for regorafenib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies. We evaluated survival and safety outcomes in patients treated with regorafenib in a real-life setting. METHODS: REBECCA is a cohort study nested within a compassionate use program designed to evaluate survival, safety, and potential prognostic factors for outcome associated with regorafenib in patients with mCRC refractory to standard therapies. Treatment effects according to various patient and tumour characteristics were evaluated using univariate and multivariate Cox proportional hazards regression models. RESULTS: Of 1178 patients in the compassionate use program, 654 were in the full analysis set. Median follow-up was 16.5 months. Median survival was 5.6 months. The 12-month survival rate was 22 %. Survival was independently and unfavourably affected by the following variables: poor performance status, short time from initial diagnosis of metastases to the start of regorafenib, low initial regorafenib dose, >3 metastatic sites, presence of liver metastases, and KRAS mutations. We identified prognostic groups of patients with low, intermediate, and high risk of death, with a median survival of 9.2, 5.2, and 2.5 months, respectively. Five-hundred-twenty-four patients (80 %) experienced at least one regorafenib-related adverse event, most commonly, fatigue, hand-foot skin reaction, diarrhea, anorexia, arterial hypertension, and mucositis. CONCLUSION: The safety and efficacy profile of regorafenib in REBECCA are similar to those in randomized trials. Our prognostic model identified subgroups of mCRC patients who derived a minimal and maximum benefit from regorafenib. TRIAL REGISTRATION: Clinicaltrials.gov NCT02310477 . More... »

PAGES

412

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-016-2440-9

DOI

http://dx.doi.org/10.1186/s12885-016-2440-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1044485147

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27389564


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Compassionate Use Trials", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins p21(ras)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Centre Oscar Lambret", 
          "id": "https://www.grid.ac/institutes/grid.452351.4", 
          "name": [
            "Medical Oncology, Centre Oscar Lambret and Catholic University, Lille, France", 
            "Department of Medical Oncology, Centre Oscar Lambret, 3, rue F Combemale, 59000, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adenis", 
        "givenName": "Antoine", 
        "id": "sg:person.01303404424.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303404424.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre L\u00e9on B\u00e9rard", 
          "id": "https://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Medical Oncology, Centre L\u00e9on B\u00e9rard, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de la Fouchardiere", 
        "givenName": "Christelle", 
        "id": "sg:person.01304763136.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304763136.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, Paul Brousse University Hospital, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paule", 
        "givenName": "Bernard", 
        "id": "sg:person.0652052661.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652052661.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Medical Oncology, Gustave Roussy, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burtin", 
        "givenName": "Pascal", 
        "id": "sg:person.01302137250.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302137250.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Poitiers", 
          "id": "https://www.grid.ac/institutes/grid.411162.1", 
          "name": [
            "Gastroenterology, University Hospital, Poitiers, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tougeron", 
        "givenName": "David", 
        "id": "sg:person.0635311430.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635311430.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Oscar Lambret", 
          "id": "https://www.grid.ac/institutes/grid.452351.4", 
          "name": [
            "Methodology and Biostatistics, Centre Oscar Lambret, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wallet", 
        "givenName": "Jennifer", 
        "id": "sg:person.013250661151.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013250661151.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, Clinique Sainte Anne, Strasbourg, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dourthe", 
        "givenName": "Louis-Marie", 
        "id": "sg:person.0645237204.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645237204.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, Hopital Priv\u00e9 des C\u00f4tes d\u2019Armor, Pl\u00e9rin, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Etienne", 
        "givenName": "Pierre-Luc", 
        "id": "sg:person.0712551042.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712551042.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut Sainte Catherine", 
          "id": "https://www.grid.ac/institutes/grid.482015.a", 
          "name": [
            "Radiation and Medical Oncology, Institut Sainte-Catherine, Avignon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mineur", 
        "givenName": "Laurent", 
        "id": "sg:person.01167577531.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167577531.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Oscar Lambret", 
          "id": "https://www.grid.ac/institutes/grid.452351.4", 
          "name": [
            "Clinical Research Unit, Centre Oscar Lambret, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clisant", 
        "givenName": "St\u00e9phanie", 
        "id": "sg:person.0762650444.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762650444.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Gastroenterology, University Hospital, Saint Etienne, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Phelip", 
        "givenName": "Jean-Marc", 
        "id": "sg:person.0775434225.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775434225.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Oscar Lambret", 
          "id": "https://www.grid.ac/institutes/grid.452351.4", 
          "name": [
            "Methodology and Biostatistics, Centre Oscar Lambret, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kramar", 
        "givenName": "Andrew", 
        "id": "sg:person.0660025350.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660025350.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology, Saint Antoine Hospital, and University Pierre et Marie Curie (UMPC), Paris VI, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Andre", 
        "givenName": "Thierry", 
        "id": "sg:person.0724247022.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724247022.53"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-1900", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018407352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)61900-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020430219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)70156-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025540135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00138-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049163362"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.33.3_suppl.678", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083955312"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-12", 
    "datePublishedReg": "2016-12-01", 
    "description": "BACKGROUND: Randomized trials have shown a survival benefit for regorafenib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies. We evaluated survival and safety outcomes in patients treated with regorafenib in a real-life setting.\nMETHODS: REBECCA is a cohort study nested within a compassionate use program designed to evaluate survival, safety, and potential prognostic factors for outcome associated with regorafenib in patients with mCRC refractory to standard therapies. Treatment effects according to various patient and tumour characteristics were evaluated using univariate and multivariate Cox proportional hazards regression models.\nRESULTS: Of 1178 patients in the compassionate use program, 654 were in the full analysis set. Median follow-up was 16.5\u00a0months. Median survival was 5.6\u00a0months. The 12-month survival rate was 22\u00a0%. Survival was independently and unfavourably affected by the following variables: poor performance status, short time from initial diagnosis of metastases to the start of regorafenib, low initial regorafenib dose, >3 metastatic sites, presence of liver metastases, and KRAS mutations. We identified prognostic groups of patients with low, intermediate, and high risk of death, with a median survival of 9.2, 5.2, and 2.5\u00a0months, respectively. Five-hundred-twenty-four patients (80\u00a0%) experienced at least one regorafenib-related adverse event, most commonly, fatigue, hand-foot skin reaction, diarrhea, anorexia, arterial hypertension, and mucositis.\nCONCLUSION: The safety and efficacy profile of regorafenib in REBECCA are similar to those in randomized trials. Our prognostic model identified subgroups of mCRC patients who derived a minimal and maximum benefit from regorafenib.\nTRIAL REGISTRATION: Clinicaltrials.gov NCT02310477 .", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-016-2440-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "name": "Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program", 
    "pagination": "412", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d3e651b2795b8f42989d476eb5457239aa27778ac1f791fa042fcd2eda6d276c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27389564"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-016-2440-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1044485147"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-016-2440-9", 
      "https://app.dimensions.ai/details/publication/pub.1044485147"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70068_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-016-2440-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2440-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2440-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2440-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-016-2440-9'


 

This table displays all metadata directly associated to this object as RDF triples.

272 TRIPLES      21 PREDICATES      54 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-016-2440-9 schema:about N071f2fd9d35b4619a4a73b6c78d295f2
2 N0d7d007f32f84817a6adcfc15340fb9c
3 N15c5e55b6323488cbed93bcac58f0e45
4 N34da2a489e9d4c52ad57a1e7cad66331
5 N51f0bdb756144d658279321db99e0576
6 N5e9b9aab3ff543feaf396ed8ded11007
7 N7011d8914ed3423caf583ab0e5c39e33
8 N7613277ae3ca4adba748f7d0cb30161e
9 N8324d0e0fe5f4cedbdb3e2867af1773a
10 N89c1725bb90e452692cb716a7c313c44
11 N9157a19e3ad54b25b764e978c7d9b7a1
12 N91c4796c87c941bcbc6bcea2714833cf
13 Na238ecd8875448b6b082236f4dbfc678
14 Na93617e7875b4247b1d6d12828aca151
15 Nabb9dc9772774a83883896d0e85fc1ee
16 Nd915bee59ba94eae89bd991cf46029f7
17 Nd991b1d355f94f809ca8164330334824
18 Ne845fc102c964670a804bd5a59c6589c
19 Nf4ed711bbe0e4ea8ace0b51f0f8c767c
20 Nfbaad09513e745d4927ee5a6ba46164f
21 anzsrc-for:11
22 anzsrc-for:1112
23 schema:author N7639f641ddff4cc6a1a805b3af257632
24 schema:citation https://doi.org/10.1016/s0140-6736(12)61900-x
25 https://doi.org/10.1016/s1470-2045(15)00138-2
26 https://doi.org/10.1016/s1470-2045(15)70156-7
27 https://doi.org/10.1158/1078-0432.ccr-11-1900
28 https://doi.org/10.1200/jco.2015.33.3_suppl.678
29 schema:datePublished 2016-12
30 schema:datePublishedReg 2016-12-01
31 schema:description BACKGROUND: Randomized trials have shown a survival benefit for regorafenib over placebo in patients with metastatic colorectal cancer (mCRC) that progressed after standard therapies. We evaluated survival and safety outcomes in patients treated with regorafenib in a real-life setting. METHODS: REBECCA is a cohort study nested within a compassionate use program designed to evaluate survival, safety, and potential prognostic factors for outcome associated with regorafenib in patients with mCRC refractory to standard therapies. Treatment effects according to various patient and tumour characteristics were evaluated using univariate and multivariate Cox proportional hazards regression models. RESULTS: Of 1178 patients in the compassionate use program, 654 were in the full analysis set. Median follow-up was 16.5 months. Median survival was 5.6 months. The 12-month survival rate was 22 %. Survival was independently and unfavourably affected by the following variables: poor performance status, short time from initial diagnosis of metastases to the start of regorafenib, low initial regorafenib dose, >3 metastatic sites, presence of liver metastases, and KRAS mutations. We identified prognostic groups of patients with low, intermediate, and high risk of death, with a median survival of 9.2, 5.2, and 2.5 months, respectively. Five-hundred-twenty-four patients (80 %) experienced at least one regorafenib-related adverse event, most commonly, fatigue, hand-foot skin reaction, diarrhea, anorexia, arterial hypertension, and mucositis. CONCLUSION: The safety and efficacy profile of regorafenib in REBECCA are similar to those in randomized trials. Our prognostic model identified subgroups of mCRC patients who derived a minimal and maximum benefit from regorafenib. TRIAL REGISTRATION: Clinicaltrials.gov NCT02310477 .
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree true
35 schema:isPartOf N243414748c174c86936692d9cd04af53
36 Na78e615830f4499d94d33cc640b2af5e
37 sg:journal.1024632
38 schema:name Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program
39 schema:pagination 412
40 schema:productId N219be843623e42329b75fda625d7cd7a
41 N2d798082fc8e4f9292b33b3dedd2b639
42 N3494c909f0154724a0dceb40c845adec
43 N6fa49d4e795d4a5b9f951734a7285e93
44 Ncb19b043d6a847a99c60a6eccf9b04b8
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044485147
46 https://doi.org/10.1186/s12885-016-2440-9
47 schema:sdDatePublished 2019-04-11T12:44
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher N32201bc2fc804218a04210a4ba562564
50 schema:url https://link.springer.com/10.1186%2Fs12885-016-2440-9
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N05411a28c92a4ab09f39b4b2ebf55302 rdf:first sg:person.0775434225.92
55 rdf:rest N06d1c31a1e3f4af38bc880d2374e08e9
56 N06d1c31a1e3f4af38bc880d2374e08e9 rdf:first sg:person.0660025350.21
57 rdf:rest Nef37140fbbfb42ecb4df1cb2aa264a65
58 N071f2fd9d35b4619a4a73b6c78d295f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Middle Aged
60 rdf:type schema:DefinedTerm
61 N0851d08099b94cc4a6240515dbcd2a18 rdf:first sg:person.0712551042.45
62 rdf:rest Nf7cd833926864b25a843f0ab7b24ddf1
63 N0d590b8b71674df9be7b5a1f243f278d rdf:first sg:person.013250661151.38
64 rdf:rest N1bfe73f4beaa4af3b8d981e85f10c7fb
65 N0d7d007f32f84817a6adcfc15340fb9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Antineoplastic Agents
67 rdf:type schema:DefinedTerm
68 N15c5e55b6323488cbed93bcac58f0e45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Proto-Oncogene Proteins p21(ras)
70 rdf:type schema:DefinedTerm
71 N1bfe73f4beaa4af3b8d981e85f10c7fb rdf:first sg:person.0645237204.25
72 rdf:rest N0851d08099b94cc4a6240515dbcd2a18
73 N219be843623e42329b75fda625d7cd7a schema:name doi
74 schema:value 10.1186/s12885-016-2440-9
75 rdf:type schema:PropertyValue
76 N243414748c174c86936692d9cd04af53 schema:issueNumber 1
77 rdf:type schema:PublicationIssue
78 N2d798082fc8e4f9292b33b3dedd2b639 schema:name readcube_id
79 schema:value d3e651b2795b8f42989d476eb5457239aa27778ac1f791fa042fcd2eda6d276c
80 rdf:type schema:PropertyValue
81 N32201bc2fc804218a04210a4ba562564 schema:name Springer Nature - SN SciGraph project
82 rdf:type schema:Organization
83 N3494c909f0154724a0dceb40c845adec schema:name dimensions_id
84 schema:value pub.1044485147
85 rdf:type schema:PropertyValue
86 N34da2a489e9d4c52ad57a1e7cad66331 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Cohort Studies
88 rdf:type schema:DefinedTerm
89 N51f0bdb756144d658279321db99e0576 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Mutation
91 rdf:type schema:DefinedTerm
92 N5e9b9aab3ff543feaf396ed8ded11007 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Kaplan-Meier Estimate
94 rdf:type schema:DefinedTerm
95 N68951d907c7146d1adfaf5a75a0c0efd rdf:first sg:person.0652052661.75
96 rdf:rest N76a316b73e854ff3b8c8dcf9c096be36
97 N6e2788865ef4400ab18224a1f2b20531 schema:name Gastroenterology, University Hospital, Saint Etienne, France
98 rdf:type schema:Organization
99 N6fa49d4e795d4a5b9f951734a7285e93 schema:name pubmed_id
100 schema:value 27389564
101 rdf:type schema:PropertyValue
102 N7011d8914ed3423caf583ab0e5c39e33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Colorectal Neoplasms
104 rdf:type schema:DefinedTerm
105 N74cd9b6a2a8449559cd711e14659e5f1 rdf:first sg:person.01304763136.25
106 rdf:rest N68951d907c7146d1adfaf5a75a0c0efd
107 N7613277ae3ca4adba748f7d0cb30161e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Adult
109 rdf:type schema:DefinedTerm
110 N7639f641ddff4cc6a1a805b3af257632 rdf:first sg:person.01303404424.36
111 rdf:rest N74cd9b6a2a8449559cd711e14659e5f1
112 N76a316b73e854ff3b8c8dcf9c096be36 rdf:first sg:person.01302137250.23
113 rdf:rest Nba257f570c2d490c94e8ca7795794823
114 N8324d0e0fe5f4cedbdb3e2867af1773a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Compassionate Use Trials
116 rdf:type schema:DefinedTerm
117 N89c1725bb90e452692cb716a7c313c44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Phenylurea Compounds
119 rdf:type schema:DefinedTerm
120 N9157a19e3ad54b25b764e978c7d9b7a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Treatment Outcome
122 rdf:type schema:DefinedTerm
123 N91c4796c87c941bcbc6bcea2714833cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Prognosis
125 rdf:type schema:DefinedTerm
126 Na238ecd8875448b6b082236f4dbfc678 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Neoplasm Metastasis
128 rdf:type schema:DefinedTerm
129 Na57e79c0e841476787ca79f0000b2b41 schema:name Medical Oncology, Clinique Sainte Anne, Strasbourg, France
130 rdf:type schema:Organization
131 Na78e615830f4499d94d33cc640b2af5e schema:volumeNumber 16
132 rdf:type schema:PublicationVolume
133 Na93617e7875b4247b1d6d12828aca151 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Female
135 rdf:type schema:DefinedTerm
136 Nabb9dc9772774a83883896d0e85fc1ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Pyridines
138 rdf:type schema:DefinedTerm
139 Nb0cf4740a3854382836ca70b945a56a1 schema:name Medical Oncology, Hopital Privé des Côtes d’Armor, Plérin, France
140 rdf:type schema:Organization
141 Nb11b29373b084b7680ead7a4ebdb865a schema:name Medical Oncology, Saint Antoine Hospital, and University Pierre et Marie Curie (UMPC), Paris VI, Paris, France
142 rdf:type schema:Organization
143 Nb315e9a962564237afca3ac05ed06ac8 schema:name Medical Oncology, Paul Brousse University Hospital, Villejuif, France
144 rdf:type schema:Organization
145 Nba257f570c2d490c94e8ca7795794823 rdf:first sg:person.0635311430.72
146 rdf:rest N0d590b8b71674df9be7b5a1f243f278d
147 Ncb19b043d6a847a99c60a6eccf9b04b8 schema:name nlm_unique_id
148 schema:value 100967800
149 rdf:type schema:PropertyValue
150 Nd915bee59ba94eae89bd991cf46029f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Aged
152 rdf:type schema:DefinedTerm
153 Nd991b1d355f94f809ca8164330334824 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Aged, 80 and over
155 rdf:type schema:DefinedTerm
156 Ndd23ff4bbb5b46b0af3706d3f3b1bc28 rdf:first sg:person.0762650444.97
157 rdf:rest N05411a28c92a4ab09f39b4b2ebf55302
158 Ne845fc102c964670a804bd5a59c6589c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Survival Analysis
160 rdf:type schema:DefinedTerm
161 Nef37140fbbfb42ecb4df1cb2aa264a65 rdf:first sg:person.0724247022.53
162 rdf:rest rdf:nil
163 Nf4ed711bbe0e4ea8ace0b51f0f8c767c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Humans
165 rdf:type schema:DefinedTerm
166 Nf7cd833926864b25a843f0ab7b24ddf1 rdf:first sg:person.01167577531.59
167 rdf:rest Ndd23ff4bbb5b46b0af3706d3f3b1bc28
168 Nfbaad09513e745d4927ee5a6ba46164f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Male
170 rdf:type schema:DefinedTerm
171 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
172 schema:name Medical and Health Sciences
173 rdf:type schema:DefinedTerm
174 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
175 schema:name Oncology and Carcinogenesis
176 rdf:type schema:DefinedTerm
177 sg:journal.1024632 schema:issn 1471-2407
178 schema:name BMC Cancer
179 rdf:type schema:Periodical
180 sg:person.01167577531.59 schema:affiliation https://www.grid.ac/institutes/grid.482015.a
181 schema:familyName Mineur
182 schema:givenName Laurent
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167577531.59
184 rdf:type schema:Person
185 sg:person.01302137250.23 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
186 schema:familyName Burtin
187 schema:givenName Pascal
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302137250.23
189 rdf:type schema:Person
190 sg:person.01303404424.36 schema:affiliation https://www.grid.ac/institutes/grid.452351.4
191 schema:familyName Adenis
192 schema:givenName Antoine
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303404424.36
194 rdf:type schema:Person
195 sg:person.01304763136.25 schema:affiliation https://www.grid.ac/institutes/grid.418116.b
196 schema:familyName de la Fouchardiere
197 schema:givenName Christelle
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304763136.25
199 rdf:type schema:Person
200 sg:person.013250661151.38 schema:affiliation https://www.grid.ac/institutes/grid.452351.4
201 schema:familyName Wallet
202 schema:givenName Jennifer
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013250661151.38
204 rdf:type schema:Person
205 sg:person.0635311430.72 schema:affiliation https://www.grid.ac/institutes/grid.411162.1
206 schema:familyName Tougeron
207 schema:givenName David
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635311430.72
209 rdf:type schema:Person
210 sg:person.0645237204.25 schema:affiliation Na57e79c0e841476787ca79f0000b2b41
211 schema:familyName Dourthe
212 schema:givenName Louis-Marie
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645237204.25
214 rdf:type schema:Person
215 sg:person.0652052661.75 schema:affiliation Nb315e9a962564237afca3ac05ed06ac8
216 schema:familyName Paule
217 schema:givenName Bernard
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0652052661.75
219 rdf:type schema:Person
220 sg:person.0660025350.21 schema:affiliation https://www.grid.ac/institutes/grid.452351.4
221 schema:familyName Kramar
222 schema:givenName Andrew
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660025350.21
224 rdf:type schema:Person
225 sg:person.0712551042.45 schema:affiliation Nb0cf4740a3854382836ca70b945a56a1
226 schema:familyName Etienne
227 schema:givenName Pierre-Luc
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712551042.45
229 rdf:type schema:Person
230 sg:person.0724247022.53 schema:affiliation Nb11b29373b084b7680ead7a4ebdb865a
231 schema:familyName Andre
232 schema:givenName Thierry
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724247022.53
234 rdf:type schema:Person
235 sg:person.0762650444.97 schema:affiliation https://www.grid.ac/institutes/grid.452351.4
236 schema:familyName Clisant
237 schema:givenName Stéphanie
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762650444.97
239 rdf:type schema:Person
240 sg:person.0775434225.92 schema:affiliation N6e2788865ef4400ab18224a1f2b20531
241 schema:familyName Phelip
242 schema:givenName Jean-Marc
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775434225.92
244 rdf:type schema:Person
245 https://doi.org/10.1016/s0140-6736(12)61900-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1020430219
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1016/s1470-2045(15)00138-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049163362
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1016/s1470-2045(15)70156-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025540135
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1158/1078-0432.ccr-11-1900 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018407352
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1200/jco.2015.33.3_suppl.678 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083955312
254 rdf:type schema:CreativeWork
255 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
256 schema:name Medical Oncology, Gustave Roussy, Villejuif, France
257 rdf:type schema:Organization
258 https://www.grid.ac/institutes/grid.411162.1 schema:alternateName Centre Hospitalier Universitaire de Poitiers
259 schema:name Gastroenterology, University Hospital, Poitiers, France
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.418116.b schema:alternateName Centre Léon Bérard
262 schema:name Medical Oncology, Centre Léon Bérard, Lyon, France
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.452351.4 schema:alternateName Centre Oscar Lambret
265 schema:name Clinical Research Unit, Centre Oscar Lambret, Lille, France
266 Department of Medical Oncology, Centre Oscar Lambret, 3, rue F Combemale, 59000, Lille, France
267 Medical Oncology, Centre Oscar Lambret and Catholic University, Lille, France
268 Methodology and Biostatistics, Centre Oscar Lambret, Lille, France
269 rdf:type schema:Organization
270 https://www.grid.ac/institutes/grid.482015.a schema:alternateName Institut Sainte Catherine
271 schema:name Radiation and Medical Oncology, Institut Sainte-Catherine, Avignon, France
272 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...